Ansager Statsautoriseret Fysioterapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 8.2% 3.1% 2.5% 3.5%  
Credit score (0-100)  0 30 54 62 47  
Credit rating  N/A BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 703 1,012 1,108 1,139  
EBITDA  0.0 230 497 440 304  
EBIT  0.0 230 495 408 272  
Pre-tax profit (PTP)  0.0 226.6 493.5 406.7 117.4  
Net earnings  0.0 176.3 391.5 316.7 54.0  
Pre-tax profit without non-rec. items  0.0 227 493 407 117  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 158 126 94.7  
Shareholders equity total  0.0 216 533 499 254  
Interest-bearing liabilities  0.0 0.0 162 79.9 320  
Balance sheet total (assets)  0.0 317 883 740 702  

Net Debt  0.0 -176 -0.7 -207 -46.2  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 703 1,012 1,108 1,139  
Gross profit growth  0.0% 0.0% 43.8% 9.5% 2.8%  
Employees  0 0 2 1 1  
Employee growth %  0.0% 0.0% 0.0% -50.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 317 883 740 702  
Balance sheet change%  0.0% 0.0% 178.2% -16.2% -5.0%  
Added value  0.0 230.0 497.3 410.2 303.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 156 -63 -63  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 3.0 4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 32.7% 49.0% 36.8% 23.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 72.5% 82.5% 50.3% 38.9%  
ROI %  0.0% 106.4% 108.7% 64.0% 48.6%  
ROE %  0.0% 81.5% 104.5% 61.4% 14.3%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 68.1% 60.3% 67.5% 36.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -76.4% -0.1% -47.2% -15.2%  
Gearing %  0.0% 0.0% 30.4% 16.0% 126.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 2.1% 1.1% 81.4%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 3.1 2.1 2.6 1.4  
Current Ratio  0.0 3.1 2.1 2.6 1.4  
Cash and cash equivalent  0.0 175.8 162.7 287.2 366.2  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 216.3 374.9 373.2 158.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 249 410 304  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 249 440 304  
EBIT / employee  0 0 248 408 272  
Net earnings / employee  0 0 196 317 54